公司简介
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli...
关联新闻
- Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Biopharmaceutical company Attovia Therapeutics said on Tuesday it was targeting a valuation of $731.5 million in its upsized initial public offering, signaling strong demand for biopharma listings.